Parkinson's drug shows promise for macular degeneration

accreditation

A common Parkinson's disease medication might hold potential for preventing or treating macular degeneration, the leading cause of vision loss in the elderly, new research suggests.

At this stage, no one is recommending that patients take the drug, levodopa (L-dopa), to thwart eye disease. But the findings are intriguing, researchers said.

No cure

"Patients taking L-dopa for any reason are much less likely to develop age-related macular degeneration.

Read: Macular Degeneration

"If they do, they develop the disease much later in life than those not taking L-dopa," said study lead author Brian McKay, an associate professor of ophthalmology and vision science at the University of Arizona.

However, the study doesn't actually prove that levodopa causes a lower incidence of age-related macular degeneration. It only uncovered an association between the two.

Age-related macular degeneration affects about 30 percent of those older than 75, McKay said.

It is caused by deterioration of the macula, the centre part of the retina, and by affecting vision, it can severely limit the ability to perform everyday activities.

Treatments can slow its progression but there is no cure, and it can lead to blindness.

Read: Getting to grips with macular degeneration

"This disease robs people of close vision," McKay said. A preventive treatment "will allow many to see their families and grandchildren as they age, and allow the aging population to keep their independence and drive, read, cook and watch TV," he said.

In the body, levodopa turns into dopamine, a naturally occurring chemical that appears linked to normal function of the retina, McKay said.

Protecting photoreceptors

In Parkinson's, insufficient dopamine contributes to movement problems.

For the study, researchers analysed medical records of 37,000 patients from a Wisconsin clinic.

The researchers looked for signs whether or not those who took levodopa had lower rates of age-related macular degeneration. They also examined a medical database of 87 million people.

The researchers found that diagnosis of age-related macular degeneration occurred, in general, around age 71. But among those who took levodopa, it occurred much later, at around age 79.

According to McKay, the drug may affect development of age-related macular degeneration by protecting parts of the eye known as photoreceptors. These neurons help the body sense light.

Levodopa, however, might not be the major player here. It's possible, McKay said, that Parkinson's disease itself could reduce the risk of age-related macular degeneration. Or there could be another scenario.

McKay mentioned that having red hair is linked to higher risks of both Parkinson's disease and age-related macular degeneration. This suggests a connection. "I am not sure the diseases are completely independent," he said.

Read: UK surgeons use stem cells to treat macular degeneration

In Parkinson's patients, levodopa causes side effects such as nausea and low blood pressure, but McKay said side effects in people without Parkinson's are unknown. He said the drug is sold over the counter and taken by body builders, among others.

Trouble for research

Levodopa is inexpensive, and that may be a big problem, said Dr Paul Bernstein, a professor of ophthalmology and visual sciences at the University of Utah School of Medicine. He wasn't involved with the study.

Since it's cheap, "many drug companies won't be interested in repurposing it," he said, noting that could spell trouble for research.

Bernstein also cautioned that this study doesn't confirm that levodopa will help people with age-related macular degeneration or those at risk for developing it.

"This is a first step," Bernstein said. "It may point to doing future studies. But I wouldn't recommend that my patients take L-dopa now. It could be dangerous."

Read: A focus on AMD

If future research proves it is effective against macular degeneration, the drug potentially could be used to treat or prevent the condition, although it's unlikely to reverse existing eye damage, McKay said.

It's unclear when clinical trials would take place.

What causes macular degeneration is unknown, although genetics, being overweight and smoking are thought to play a role, according to the American Macular Degeneration Foundation. Whites are more vulnerable than blacks and Hispanics to the condition.

The study was published in the American Journal of Medicine

Read more: 

Genes blamed for vision loss  

Fish oil cuts blindness risk  

Your complete guide to lycopene 

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
The ANC's leadership race is heating up. Who do you think will be elected party president at Nasrec in December?
Please select an option Oops! Something went wrong, please try again later.
Results
Nkosazana Dlamini-Zuma has got it in the bag
7% - 833 votes
I foresee a second term for Cyril Ramaphosa
83% - 9574 votes
Don’t discount a Zweli Mkhize win
10% - 1116 votes
Vote
Rand - Dollar
17.99
+0.1%
Rand - Pound
20.13
-0.2%
Rand - Euro
17.65
-0.1%
Rand - Aus dollar
11.55
-0.0%
Rand - Yen
0.12
-0.2%
Gold
1,711.80
-0.1%
Silver
20.75
+0.4%
Palladium
2,255.50
-0.3%
Platinum
932.50
+0.8%
Brent Crude
94.42
+1.1%
Top 40
59,198
-0.4%
All Share
65,573
-0.4%
Resource 10
63,523
+0.4%
Industrial 25
79,396
-0.8%
Financial 15
13,959
-0.3%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE